DK3173071T3 - Formularing af maropitant - Google Patents

Formularing af maropitant Download PDF

Info

Publication number
DK3173071T3
DK3173071T3 DK16200848.6T DK16200848T DK3173071T3 DK 3173071 T3 DK3173071 T3 DK 3173071T3 DK 16200848 T DK16200848 T DK 16200848T DK 3173071 T3 DK3173071 T3 DK 3173071T3
Authority
DK
Denmark
Prior art keywords
maropitant
formulation
Prior art date
Application number
DK16200848.6T
Other languages
English (en)
Other versions
DK3173071T4 (da
Inventor
Marinus Maria Martinus Boeren
Rudolf Johannes Paridaans
Original Assignee
Le Vet B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57460319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3173071(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Le Vet B V filed Critical Le Vet B V
Application granted granted Critical
Publication of DK3173071T3 publication Critical patent/DK3173071T3/da
Publication of DK3173071T4 publication Critical patent/DK3173071T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16200848.6T 2015-11-27 2016-11-28 Maropitantformulering DK3173071T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2015865A NL2015865B1 (en) 2015-11-27 2015-11-27 Maropitant Formulation.

Publications (2)

Publication Number Publication Date
DK3173071T3 true DK3173071T3 (da) 2021-06-28
DK3173071T4 DK3173071T4 (da) 2026-02-09

Family

ID=57460319

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16200848.6T DK3173071T4 (da) 2015-11-27 2016-11-28 Maropitantformulering

Country Status (13)

Country Link
EP (1) EP3173071B2 (da)
CY (1) CY1124893T1 (da)
DK (1) DK3173071T4 (da)
ES (1) ES2873376T5 (da)
FI (1) FI3173071T4 (da)
HR (1) HRP20210986T4 (da)
HU (1) HUE054584T2 (da)
LT (1) LT3173071T (da)
NL (1) NL2015865B1 (da)
PL (1) PL3173071T5 (da)
PT (1) PT3173071T (da)
RS (1) RS62057B2 (da)
SI (1) SI3173071T2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
AU2018290889B2 (en) 2017-06-30 2024-06-27 Alto Neuroscience, Inc. NK-1 antagonist compositions and methods for use in treating depression
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法
MX2023009141A (es) * 2021-02-05 2023-08-17 Intelgenx Corp Formulacion de pelicula oral de alta carga.
AT527172A1 (de) * 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6340166A (ja) 1986-08-06 1988-02-20 Fuji Xerox Co Ltd 電子写真感光体
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
HUE034099T2 (en) 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
BRPI0514408B8 (pt) 2004-08-24 2021-05-25 Asubio Pharma Co Ltd preparação liquida de peptídeo fisiologicamente ativo
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
CN103637987B (zh) 2013-12-09 2015-12-02 韩彬 羟考酮的液体药物组合物

Also Published As

Publication number Publication date
LT3173071T (lt) 2021-07-12
ES2873376T3 (es) 2021-11-03
EP3173071A1 (en) 2017-05-31
PT3173071T (pt) 2021-04-15
RS62057B1 (sr) 2021-07-30
EP3173071B2 (en) 2025-12-24
HRP20210986T1 (hr) 2021-09-17
SI3173071T2 (sl) 2026-04-30
RS62057B2 (sr) 2026-03-31
HUE054584T2 (hu) 2021-09-28
SI3173071T1 (sl) 2021-11-30
NL2015865B1 (en) 2017-06-13
EP3173071B1 (en) 2021-03-24
PL3173071T5 (pl) 2026-02-09
CY1124893T1 (el) 2023-01-05
DK3173071T4 (da) 2026-02-09
PL3173071T3 (pl) 2021-08-16
FI3173071T4 (fi) 2026-02-06
ES2873376T5 (en) 2026-04-16
HRP20210986T4 (hr) 2026-03-13

Similar Documents

Publication Publication Date Title
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
SI3769781T1 (sl) Stabilna formulacija proti-IFNAR1
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3220891T3 (da) Sublingual formulering af riluzol
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3474822T3 (da) Formuleringer af brincidofovir
DK3283210T3 (da) Fremgangsmåde
DK3307267T3 (da) Behandling af multipel sklerose
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3418273T3 (da) Derivater af flavagliner
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK2910535T3 (da) Sammensætning til anvendelse af ekspanderet perlit
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
IL254502B (en) Solid forms of menaquinols
DK3678644T3 (da) Formuleringer af copanlisib
DK3316857T3 (da) Multifasiske sammensætninger
DK3310331T3 (da) Injicerbare farmaceutiske formuleringer af lefamulin
IL258630A (en) Formulation of l-ornithine phenylacetate